FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308731659> ?p ?o ?g. }

• W4308731659 endingPage "41" @default.
• W4308731659 startingPage "31" @default.
• W4308731659 abstract "CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy are considered standard-of-care for first-line therapy of patients with hormone receptor positive, HER2 negative, advanced breast cancer (HR+/HER2- ABC). Superiority of combination therapy over endocrine monotherapy has been demonstrated in a multitude of randomized controlled trials (RCTs) in phase III and IV. However, RCTs reflect clinical reality only to a limited extent, as narrow inclusion criteria lead to a selected patient collective. Here, we present real-world data (RWD) on CDK4/6i treatment in patients with HR+/HER2- ABC at four certified German university breast cancer centers.Patients diagnosed with HR+/HER2- ABC who were treated in clinical routine with CDK4/6i between November 2016 and December 2020 at four certified German university breast cancer centers (Saarland University Medical Center, University Medical Center Charité Berlin, University Medical Center Bonn, and University Medical Center Hospital Schleswig-Holstein, Campus Kiel) were identified and enrolled in this retrospective study. Clinicopathological characteristics and clinical outcomes were recorded with particular emphasis on CDK4/6i therapy course [progression-free survival (PFS) following treatment initiation, toxicity, dose reduction, therapy discontinuation, prior and subsequent therapy line].Data from n = 448 patients were evaluated. The mean patient age was 63 (±12) years. Of these patients, n = 165 (36.8%) were primarily metastasized, and n = 283 (63.2%) had secondary metastatic disease. N = 319 patients (71.3%) received palbociclib, n = 114 patients (25.4%) received ribociclib, and n = 15 patients (3.3%) received abemaciclib, respectively. Dose reduction was performed in n = 132 cases (29.5%). N = 57 patients (12.7%) discontinued the treatment with CDK4/6i due to side effects. N = 196 patients (43.8%) experienced disease progression under CDK4/6i treatment. The median PFS was 17 months. Presence of hepatic metastases and prior therapy lines were associated with shorter PFS, whereas estrogen positivity and dose reduction due to toxicity were positively associated with PFS. Presence of bone and lung metastases, progesterone positivity, Ki67 index, grading, BRCA1/2 and PIK3CA mutation status, adjuvant endocrine resistance, and age did not significantly impact on PFS.Our RWD analysis on CDK4/6i treatment in Germany supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2- ABC. In comparison to data from the pivotal RCTs, median PFS was lower but within the expected range for RWD, which could result from inclusion of patients with more advanced diseases (i.e., higher therapy lines) to our dataset." @default.
• W4308731659 created "2022-11-15" @default.
• W4308731659 creator A5004686505 @default.
• W4308731659 creator A5009090947 @default.
• W4308731659 creator A5013727283 @default.
• W4308731659 creator A5017755525 @default.
• W4308731659 creator A5019545790 @default.
• W4308731659 creator A5024741688 @default.
• W4308731659 creator A5026211073 @default.
• W4308731659 creator A5056631152 @default.
• W4308731659 creator A5064646135 @default.
• W4308731659 creator A5081832847 @default.
• W4308731659 creator A5085546495 @default.
• W4308731659 creator A5088720640 @default.
• W4308731659 date "2022-12-06" @default.
• W4308731659 modified "2023-10-06" @default.
• W4308731659 title "CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis" @default.
• W4308731659 cites W1974872610 @default.
• W4308731659 cites W2000468408 @default.
• W4308731659 cites W2000612276 @default.
• W4308731659 cites W2019151692 @default.
• W4308731659 cites W2136488739 @default.
• W4308731659 cites W2204530481 @default.
• W4308731659 cites W2290950904 @default.
• W4308731659 cites W2310580441 @default.
• W4308731659 cites W2560635244 @default.
• W4308731659 cites W2616160160 @default.
• W4308731659 cites W2620993107 @default.
• W4308731659 cites W2781844803 @default.
• W4308731659 cites W2804105316 @default.
• W4308731659 cites W2805575723 @default.
• W4308731659 cites W2896124038 @default.
• W4308731659 cites W2897446380 @default.
• W4308731659 cites W2908699784 @default.
• W4308731659 cites W2913253891 @default.
• W4308731659 cites W2976415870 @default.
• W4308731659 cites W3047973464 @default.
• W4308731659 cites W3082552926 @default.
• W4308731659 cites W3093770202 @default.
• W4308731659 cites W3123151883 @default.
• W4308731659 cites W3133509869 @default.
• W4308731659 cites W3174841530 @default.
• W4308731659 cites W3203452321 @default.
• W4308731659 cites W4213275140 @default.
• W4308731659 cites W4221085715 @default.
• W4308731659 doi "https://doi.org/10.1159/000527917" @default.
• W4308731659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36876172" @default.
• W4308731659 hasPublicationYear "2022" @default.
• W4308731659 type Work @default.
• W4308731659 citedByCount "4" @default.
• W4308731659 countsByYear W43087316592023 @default.
• W4308731659 crossrefType "journal-article" @default.
• W4308731659 hasAuthorship W4308731659A5004686505 @default.
• W4308731659 hasAuthorship W4308731659A5009090947 @default.
• W4308731659 hasAuthorship W4308731659A5013727283 @default.
• W4308731659 hasAuthorship W4308731659A5017755525 @default.
• W4308731659 hasAuthorship W4308731659A5019545790 @default.
• W4308731659 hasAuthorship W4308731659A5024741688 @default.
• W4308731659 hasAuthorship W4308731659A5026211073 @default.
• W4308731659 hasAuthorship W4308731659A5056631152 @default.
• W4308731659 hasAuthorship W4308731659A5064646135 @default.
• W4308731659 hasAuthorship W4308731659A5081832847 @default.
• W4308731659 hasAuthorship W4308731659A5085546495 @default.
• W4308731659 hasAuthorship W4308731659A5088720640 @default.
• W4308731659 hasBestOaLocation W43087316591 @default.
• W4308731659 hasConcept C121608353 @default.
• W4308731659 hasConcept C126322002 @default.
• W4308731659 hasConcept C143998085 @default.
• W4308731659 hasConcept C2775930923 @default.
• W4308731659 hasConcept C2777176818 @default.
• W4308731659 hasConcept C2778715236 @default.
• W4308731659 hasConcept C2779744173 @default.
• W4308731659 hasConcept C2780482068 @default.
• W4308731659 hasConcept C29456083 @default.
• W4308731659 hasConcept C530470458 @default.
• W4308731659 hasConcept C535046627 @default.
• W4308731659 hasConcept C71924100 @default.
• W4308731659 hasConceptScore W4308731659C121608353 @default.
• W4308731659 hasConceptScore W4308731659C126322002 @default.
• W4308731659 hasConceptScore W4308731659C143998085 @default.
• W4308731659 hasConceptScore W4308731659C2775930923 @default.
• W4308731659 hasConceptScore W4308731659C2777176818 @default.
• W4308731659 hasConceptScore W4308731659C2778715236 @default.
• W4308731659 hasConceptScore W4308731659C2779744173 @default.
• W4308731659 hasConceptScore W4308731659C2780482068 @default.
• W4308731659 hasConceptScore W4308731659C29456083 @default.
• W4308731659 hasConceptScore W4308731659C530470458 @default.
• W4308731659 hasConceptScore W4308731659C535046627 @default.
• W4308731659 hasConceptScore W4308731659C71924100 @default.
• W4308731659 hasIssue "1" @default.
• W4308731659 hasLocation W43087316591 @default.
• W4308731659 hasLocation W43087316592 @default.
• W4308731659 hasLocation W43087316593 @default.
• W4308731659 hasOpenAccess W4308731659 @default.
• W4308731659 hasPrimaryLocation W43087316591 @default.
• W4308731659 hasRelatedWork W2292433415 @default.
• W4308731659 hasRelatedWork W2740803632 @default.
• W4308731659 hasRelatedWork W2751810360 @default.

• next